Completed PHASE4 INTERVENTIONAL 2-arm NCT04723563

Nebulized Heparin for the Treatment of COVID-19 (INHALE-HEP)

INHALEd Unfractionated HEParin for the Treatment of Hospitalized Patients With COVID-19 Pneumonia

Sponsor: Frederick Health

Interventions 0.9%sodium chloride Heparin

Updated 5 times since 2021 Last updated: Sep 3, 2021 Started: Feb 22, 2021 Primary completion: Aug 23, 2021 Completion: Aug 23, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Covid19 and Pneumonia, Viral and is currently completed. Frederick Health leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Oct 2021 — Jul 2024 [monthly]

Completed PHASE4

Status: Enrolling By Invitation → Completed
Mar 2021 — Oct 2021 [monthly]

Enrolling By Invitation PHASE4

Status: Not Yet Recruiting → Enrolling By Invitation
Feb 2021 — Mar 2021 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Frederick Health

Data source: Frederick Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Frederick, United States